Pertuzumab trials for HER2-positive Breast Cancer
All Pertuzumab trials · All HER2-positive Breast Cancer trials
8
Recruiting trials
Phase breakdown
Phase 2 6Phase 3 3
Recruiting trials studying Pertuzumab for HER2-positive Breast Cancer
- A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
- A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
- A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
- BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
- Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
- IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
- Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
Common questions
How many trials study Pertuzumab for HER2-positive Breast Cancer?
8 recruiting trials.
Is this list complete?
No. For the full record, search ClinicalTrials.gov.